Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

Condition:   Cataract Interventions:   Drug: Nepafenac 0.3% Oph Susp;   Drug: Placebos;   Drug: Nepafenac 0.3% Oph Susp (reference) Sponsor:   Actavis Inc. Recruiting

Source: ClinicalTrials.gov - April 17, 2018 Category: Research Source Type: clinical trials